BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avid Bioservices, Inc. Signs Product Development Agreement With MediPharm Biotech, Inc. For Tumor Necrosis Therapy


10/19/2005 5:10:47 PM

TUSTIN, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc., a wholly-owned subsidiary of Peregrine Pharmaceuticals , announced today it has signed a product development agreement with Medipharm Biotech, Co., Ltd. of Shanghai, China for process and product development of Tumor Necrosis Therapy (TNT) under current Good Manufacturing Practices (cGMP). Avid will provide the process development and manufacturing services to assist Medipharm in preparing for commercial launch of their radiolabeled TNT antibody in the Peoples Republic of China (PRC).

"We are very happy to be able to assist Medipharm as they make preparations for the commercial launch of TNT," said Jay Treat, Ph.D., Avid's vice president of business development. "This is a comprehensive project in which Avid will provide process development, scale-up and cGMP manufacturing of Medipharm's TNT monoclonal antibody."

MediPharm received product approval for Iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) monoclonal antibody in the Peoples Republic of China. The issuance of the Certificate of New Drug from the State Food and Drug Administration (SFDA) of China for Iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) monoclonal antibody for the treatment of advanced lung cancer represents the first radiolabeled monoclonal antibody approved for cancer therapy in China.

About Avid Bioservices

Avid Bioservices provides a full range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid operates a state-of- the-art cGMP biologics contract manufacturing facility and production laboratories in Tustin, California. The company's comprehensive package of services includes mammalian cell culture, process development, analytical method development and regulatory support in addition to cGMP manufacturing, purification and bulk packaging. Avid has 10 years of antibody manufacturing experience producing monoclonal antibodies to support clinical trials ranging from Phase I to Phase III. Avid personnel have experience manufacturing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes. For more information about Avid, please visit http://www.avidbio.com/ . Information on Peregrine Pharmaceuticals, Inc. may be found at http://www.peregrineinc.com/ .

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, Peregrine's report on Form 10-K for the year ended April 30, 2003 and on Form 10-Q for the quarter ended July 31, 2003.

Investor Relations Contacts: Frank Hawkins and Julie Marshall Hawk Associates, Inc. (800) 987-8256 or info@hawkassociates.com

Avid Bioservices, Inc.

CONTACT: Investor Relations, Frank Hawkins or Julie Marshall, both ofHawk Associates, Inc., +1-800-987-8256, or info@hawkassociates.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES